Montelukast Rudipharm (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Rudipharm, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Rudipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across multiple markets. The product meets EU standards and is manufactured under GMP conditions, with rigorous quality testing for patient safety.

Montelukast acts on leukotriene pathways to control airway inflammation and bronchoconstriction.

- Asthma: reduces frequency of wheezing episodes and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by allergens. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness, sometimes with vomiting. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests indicating possible liver injury.

When prescribing Montelukast, clinicians should consider several safety precautions.

- Assess liver function: evaluate baseline hepatic enzymes in patients with liver disease. - Monitor neuropsychiatric status: watch for mood swings, depression or suicidal ideation. - Use as maintenance therapy only: it is not intended for acute asthma attacks. - Avoid in known hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Montelukast may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness by inducing metabolism. - Ketoconazole: may raise montelukast levels, increasing risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential for increased INR, requiring closer monitoring. - Beta‑agonists: additive bronchodilatory effect may enhance symptom control. - Theophylline: combined use may affect respiratory response, necessitating observation.